Immunic's (IMUX) "Buy" Rating Reaffirmed at D. Boral Capital

Immunic (NASDAQ:IMUX - Get Free Report)'s stock had its "buy" rating reissued by equities research analysts at D. Boral Capital in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $17.00 price target on the stock.

A number of other brokerages have also recently issued reports on IMUX. HC Wainwright reissued a "buy" rating and set a $10.00 price target on shares of Immunic in a research report on Friday, February 21st. William Blair started coverage on Immunic in a research report on Tuesday, March 25th. They set an "outperform" rating for the company. Finally, StockNews.com cut Immunic from a "hold" rating to a "sell" rating in a research note on Thursday, March 20th. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $13.20.

Immunic Stock Performance

Shares of Immunic stock traded up $0.04 during midday trading on Thursday, reaching $0.96. 295,107 shares of the company's stock traded hands, compared to its average volume of 621,479. The stock has a 50 day moving average of $1.08 and a 200-day moving average of $1.15. The company has a market cap of $86.44 million, a PE ratio of -0.78 and a beta of 1.91. Immunic has a 12 month low of $0.83 and a 12 month high of $2.11.

Remove Ads

Institutional Trading of Immunic

Several large investors have recently modified their holdings of the company. Millennium Management LLC boosted its position in Immunic by 480.6% in the fourth quarter. Millennium Management LLC now owns 579,683 shares of the company's stock worth $580,000 after purchasing an additional 479,846 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Immunic by 45.6% during the 4th quarter. Renaissance Technologies LLC now owns 566,623 shares of the company's stock worth $567,000 after acquiring an additional 177,542 shares during the last quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Immunic by 90.0% during the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 204,579 shares of the company's stock valued at $205,000 after acquiring an additional 96,894 shares during the period. Barclays PLC purchased a new stake in shares of Immunic in the 4th quarter worth $84,000. Finally, HB Wealth Management LLC bought a new stake in Immunic during the fourth quarter valued at about $81,000. Institutional investors own 51.82% of the company's stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.